Free Consultation 215.567.2010


Members of our Pharmaceuticals team apply their legal expertise and advanced degrees in chemistry, pharmacy and other disciplines to provide our clients with legal services including:

  • Patentability Opinions
  • Freedom to Operate Opinions
  • Patent Preparation, Prosecution and Procurement
  • Representation in Post-Grant Proceedings in the U.S. Patent and Trademark Office, Including Interferences, Reexaminations, Inter Partes Review, and Post Grant Reviews
  • Due Diligence Studies
  • License counseling, negotiation and drafting
  • Alternative Dispute Resolution
  • Litigation, including patent infringement and ANDA litigation
  • ANDA development and design of finished dosage forms
  • Patent protection, enforcement and design around drug delivery forms and molecules

Related Representative Matters

  • Served as an arbitrator in a dispute over alleged breaches of a license agreement for proprietary rights relating to cannabis transdermal patches, plus counterclaims for fraud and tortious interference
  • Boehringer et al. v. InvaGen (10/25/18 D.NJ) represented generic in ANDA litigation successfully invalidating asserted patents covering Tradjenta® (linagliptin) and Jentadueto® (linagliption and metformin)
  • Prepared memorandum on patent infringement damages for pharmaceutical client and assisted in decision which saved hundreds of millions of dollars
  • Successfully represented generic pharmaceutical company in ANDA litigation involving Niaspan® (niacin extended release)
  • In re ‘318 Patent Litigation, 578 F.Supp.2d 711 (D. Del. 2008), aff’d, 583 F.3d 1317 (Fed. Cir. 2009). Represented one of generic manufacturers in a patent infringement suit filed under 35 U.S.C. § 271(c)(2) regarding ANDA filing for an Alzheimer’s drug sold under the name Razdyne®/Reminyl® (galanthamine)
  • Sanofi-Aventis, Sanofi-Synthelabo, Inc., and Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership v. Apotex, Inc., represented generic in ANDA litigation on Plavix® involving largest at risk launch in history
  • Roxane Labs Inc. v. Invagen Inc., successfully represented defendant generic company in transferring case from Ohio to NJ, defeated Preliminary Injunction, affirmed on appeal and obtained stipulation of non-infringement, affirmed on appeal, in suit by another generic regarding calcium acetate tablets (PhosLo® brand) and ultimately awarded client $2 million in attorney fees finding the case “exceptional”
  • Genzyme v. Pentech Pharmaceuticals, Inc. represented generic in ANDA litigation on Hectorol® invalidating 2 Orange Book listed patents, with third patent being delisted as a result of suit
  • Biovail Laboratories, Inc. v. Torpharm. Inc., successfully represented generic company in ANDA litigation involving Tiazac® (diltiazem hydrochloride)
  • Represented a leading multinational life sciences company in freedom-to-operate clearance searches and licensing opportunity identification


1635 Market Street, 12th Floor
Philadelphia, Pennsylvania 19103-2212

215-567-2010 | 215-751-1142

View Map

Lehigh Valley

6081 Hamilton Blvd Suite 600
Allentown, Pennsylvania 18106

610-255-7551 | 610-255-7542

View Map